VP of Technical Development, Cell and Individualized Therapy
Genentech
Andy is currently the VP of Technical Development, Cell and Individualized Therapy at Genentech. He has held various CMC roles at Genentech, including leading the launches for POLIVY (anti-CD79b-vcMMAE ADC) and SUSVIMO (port delivery system for ranibizumab) as well as overseeing biologics bioprocess functions. Prior to Genentech, Andy held various positions in process development, analytical development and manufacturing at Cell Genesys, Inc. and Chiron Corp.. He received his Ph.D. in Biochemical Engineering from Northwestern University and BS in Chemical Engineering from the University of California, Berkeley.